Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes and late effects of surgery and radiotherapy in adult intracranial ependymoma patients.

Journal of neuro-oncology·2026
Same author

Improved coping and self-efficacy drive improvements in mood among caregivers of patients with primary malignant brain tumors: Results from an RCT.

Neuro-oncology·2026
Same author

Empowering Neurosurgical Leadership: Training the Next Generation of Neurosurgical Leaders.

Neurosurgery·2026
Same author

Use of a Novel Intraoperative Neurocognitive Monitoring Task During Awake Craniotomy for Tumor Resection in the Language-Dominant Parietal Lobe.

Operative neurosurgery (Hagerstown, Md.)·2026
Same author

Cognitive function, quality of life, and survival outcomes in patients with lower grade gliomas treated with proton radiation therapy: A phase II study.

Neuro-oncology·2026
Same author

Protocol for the systematic reduction of sterile surgical instrument waste: a single-institution prospective implementation and analysis.

Journal of neurosurgery·2026
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

3.2K

Low-grade gliomas.

Deborah A Forst1, Brian V Nahed, Jay S Loeffler

  • 1Departments of Neurology, Neurosurgery, and Radiation Oncology, and Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

The Oncologist
|March 26, 2014
PubMed
Summary
This summary is machine-generated.

Low-grade gliomas (LGGs) are slow-growing brain tumors. Management requires balancing treatment benefits against risks, considering molecular profiles and impact on quality of life.

Keywords:
AstrocytomaGliomaOligodendrogliomaRadiationSurgery

More Related Videos

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.3K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.6K

Related Experiment Videos

Last Updated: May 1, 2026

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

3.2K
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

1.3K
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.6K

Area of Science:

  • Neuro-oncology
  • Oncology
  • Genetics

Background:

  • Low-grade gliomas (LGGs) are primary brain tumors often diagnosed in young patients.
  • LGGs typically exhibit an indolent clinical course with prolonged survival compared to high-grade gliomas.
  • Management decisions for LGGs are complex due to the need to balance treatment efficacy with potential long-term risks.

Purpose of the Study:

  • To review current management strategies for low-grade gliomas.
  • To highlight the significance of molecular profiling in developing targeted therapies for LGGs.
  • To evaluate the impact of LGG treatment on neurocognitive function and quality of life.

Main Methods:

  • Review of current literature on low-grade glioma management.
  • Analysis of surgical, radiotherapeutic, and chemotherapeutic approaches.
  • Evaluation of molecular profiling techniques and their role in targeted therapy development.

Main Results:

  • Individualized treatment approaches for LGGs are based on tumor characteristics and patient factors.
  • Molecular profiling is crucial for advancing targeted therapies.
  • Treatment decisions must consider potential effects on neurocognition and quality of life.

Conclusions:

  • Current management of LGGs involves a multidisciplinary approach, including surgery, radiation, and chemotherapy.
  • Targeted therapies based on genetic and molecular properties hold promise for improved outcomes.
  • Preserving neurocognitive function and quality of life is a critical consideration in LGG patient care.